# Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer

> **NCT04210492** · PHASE1,PHASE2 · RECRUITING · sponsor: **Yale University** · enrollment: 36 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **RADIATION:** 45 Gray (Gy) regimen

## Key facts

- **NCT ID:** NCT04210492
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-08-26
- **Primary completion:** 2030-01
- **Final completion:** 2030-01
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04210492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04210492, "Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04210492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*